Home > Healthcare > Pharmaceuticals > Finished Drug Form > Cervical Cancer Treatment Market

Cervical Cancer Treatment Market Trends

Report ID: GMI10222
Published Date: Jul 2024
Report Format: PDF

Download Free Sample

Cervical Cancer Treatment Market Trends

Human papillomavirus (HPV) infections are a primary risk factor for cervical cancer. The increasing prevalence of HPV infections globally directly correlates with higher incidences of cervical cancer. For instance, according to the Centers for Disease Control and Prevention, over 90% of cervical cancer cases are linked to HPV infection. Annually in the U.S., about 200,000 women are diagnosed with cervical precancer, while approximately 11,100 cases of cervical cancer are caused by HPV.
Tragically, around 4,000 women lose their lives to cervical cancer each year. Therefore, as the number of HPV infections rises, so does the demand for effective treatments for HPV-related cervical cancers.
There has been a notable increase in research and development funding aimed at cancer treatments, including cervical cancer. This funding supports the development of innovative therapies, novel drug delivery systems, diagnostic tools, and preventive measures. Advances in treatment options and technologies attract investments from pharmaceutical companies and research institutions, driving market expansion.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Cervical cancer treatment market size was valued at USD 8.2 billion in 2023 and is estimated to grow at 5.3% CAGR from 2024 to 2032 due to the rising prevalence of cervical cancer globally.

The treatment segment in the market accounted for USD 5.5 billion in 2023 attributed to the increasing adoption of advanced therapies and pharmaceuticals tailored to combat cervical cancer effectively.

U.S. cervical cancer treatment market is projected to reach USD 4.8 billion by 2032 owing to the rising incidence and prevalence of cervical cancer.

AbbVie Inc., AstraZeneca PLC, Biocon Limited, Mylan N.V., Bristol-Myers Squibb Company, Eli Lilly And Company, F. Hoffmann-La Roche Ltd, Fresenius SE & Co. KGaA, GSK plc, Hikma Pharmaceuticals PLC, McKesson Corporation, and Merck & Co., Inc. among others.